tradmap

RXRX Recursion Pharmaceuticals, Inc.

$3.43 +1.63%

Updated

Healthcare · Biological Products, (No Diagnostic Substances)

Recursion Pharmaceuticals, Inc. (RXRX) is a healthcare company in the Biological Products, (No Diagnostic Substances) industry, with a market capitalization of $1.8 billion. Shares last traded at $3.43, 52.2% below their 52-week high. Over the past year the stock is down 25.6%. Net profit margin is -945.9%, below the peer median of 5.3%. Revenue grew 26.9% year over year.

Market Cap
$1.8B
Shares Out
535.3M
EPS (TTM)
$-2.87
P/E Ratio
P/S Ratio
33.47
P/B Ratio
2.01
Dividend / Share
Dividend Yield
52-Week High
$7.18
52-Week Low
$2.77
Volume
704,860
Avg Vol (3m)
884,056.397

Performance

1W
-0.58%
1M
+8.03%
3M
-9.38%
6M
-3.24%
YTD
-18.53%
1Y
-25.60%

Daily candles · volume · SMA(20)/SMA(50) · Databento EQUS.MINI.

Technicals

RSI (14)
54.08
SMA (50)
$3.32
SMA (200)
$3.65
Price vs SMA50
+3.28%
Price vs SMA200
-5.98%
ATR (14)
$0.18

Full technical analysis (26 indicators, D/W/M) →

Financials

Revenue
$55M
Net Income
$-519M
Gross Margin
3.5%
Operating Margin
-991.7%
Net Margin
-945.9%
Return on Equity
-56.7%
Return on Assets
-42.8%
Current Ratio
5.03
Debt / Equity
0.00
Revenue Growth (YoY)
+26.9%

Latest reported annual period ending 2026-06-30 · SEC EDGAR/XBRL.

Full financials — revenue, cash flow & debt over time →

Recent earnings

PeriodEPS (diluted)Reported
Q2 2026 $-0.47 2026-08-05
Q1 2026 $-0.22 2026-05-06
FY 2025 $-1.44 2026-02-25
Q3 2025 $-1.27 2025-11-05
Q2 2026 $-0.91 2026-08-05
Q1 2026 $-0.50 2026-05-06

Full earnings history →

Biological Products, (No Diagnostic Substances) peers

RXRX vs 14 industry peers (Biological Products, (No Diagnostic Substances)), by market cap. Updated

P/S vs peers
33.47 / 19.49 med
+72% premium
Net margin vs peers
-945.9% / 5.3% med
below median
1–14 of 14
AMGNAmgen$240.1B27.476.3023.0%+0.31%
GILDGilead Sciences$187.5B-57.876.16-10.6%+1.09%
MRNAModerna$58.8B-18.68-1.94%
RVMDRevolution Medicines, Inc.$45.2B-25.55+0.76%
BIIBBiogen$33.1B24.163.3413.8%+0.78%
NBIXNeurocrine Biosciences Inc$16.1B22.814.7720.9%+0.33%
EXELExelixis, Inc.$14.7B17.036.0235.3%+1.00%
HALOHalozyme Therapeutics, Inc.$12.6B30.397.5524.9%+1.01%
TECHBio-Techne$11.4B62.489.3515.0%+0.21%
KRYSKrystal Biotech, Inc.$11.0B45.5224.9554.8%+0.58%
APGEApogee Therapeutics, Inc.$10.2B-34.57+0.04%
KYMRKymera Therapeutics, Inc.$9.7B-32.51-1.24%
RGENRepligen Corp$9.6B230.5312.205.3%-1.87%
PCVXVaxcyte, Inc.$9.1B-8.56-0.62%

Source: SEC EDGAR (fundamentals/EPS/dividends) · Databento EQUS.MINI (prices) · market cap & yield computed by tradmap. Informational only — not financial advice.